Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells

Respiratory Research

Volumn 7, Issue , 2006, Pages

  Growcott, Ellena J ^a   Spink, Karen G ^b   Ren, Xiaohui ^a   Afzal, Saliha ^a,c   Banner, Kathy H ^b,d   Wharton, John ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CICAPROST; CILOMILAST; CYCLIC AMP; CYCLIC AMP PHOSPHODIESTERASE; DNA FRAGMENT; FORSKOLIN; GELATINASE A; GELATINASE B; ILOPROST; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PLATELET DERIVED GROWTH FACTOR BB; PROSTACYCLIN DERIVATIVE; ROFLUMILAST; ROLIPRAM; SPLEEN EXONUCLEASE; AMINOPYRIDINE DERIVATIVE; BENZAMIDE DERIVATIVE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1; CYCLOPROPANE DERIVATIVE; DNA; METALLOPROTEINASE; PDE4A PROTEIN, HUMAN; PHOSPHODIESTERASE INHIBITOR;

APOPTOSIS; ARTERY MUSCLE; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS; EXPLANT; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROLYSIS; INHIBITION KINETICS; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; SMOOTH MUSCLE FIBER; BIOSYNTHESIS; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; GENETICS; INTRACELLULAR MEMBRANE; METABOLISM; PHYSIOLOGY; VASCULAR SMOOTH MUSCLE;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; AMINOPYRIDINES; APOPTOSIS; BENZAMIDES; CELL PROLIFERATION; CELLS, CULTURED; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 1; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; CYCLOPROPANES; DNA; GENE EXPRESSION; HUMANS; ILOPROST; INTRACELLULAR MEMBRANES; METALLOPROTEASES; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHOSPHODIESTERASE INHIBITORS; PULMONARY ARTERY;

EID: 33644620786     PISSN: 1465993X     EISSN: None     Source Type: Journal    
DOI: 10.1186/1465-9921-7-9     Document Type: Article

References (53)

1. Runo JR, Loyd JE: Primary pulmonary hypertension. Lancet 2003, 361:1533-1544.
2. Cowan KN, Jones PL, Rabinovitch M: Regression of hypertrophied rat pulmonary arteries in organ culture is associated with suppression of proteolytic activity, inhibition of tenascin-C, and smooth muscle cell apoptosis. Circ Res 1999, 84:1223-1233.
3. McMurtry MS, Archer SL, Altieri DC, Bonnet S, Haromy A, Harry G, et al.: Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 2005, 115:1479-1491.
4. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, et al.: Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005, 115:2811-2821.
5. Houslay MD, Milligan G: Tailoring cAMP-signalling responses through isoform multiplicity. Trends Biochem Sci 1997, 22:217-224.
6. Olschewski H, Rose F, Schermuly R, Ghofrani HA, Enke B, Olschewski A, et al.: Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol Ther 2004, 102:139-153.
7. Wharton J, Davie N, Upton PD, Yacoub MH, Polak JM, Morrell NW: Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells. Circulation 2000, 102:3130-3136.
8. Clapp LH, Finney P, Turcato S, Tran S, Rubin LJ, Tinker A: Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol 2002, 26:194-201.
9. Schermuly RT, Inholte C, Ghofrani HA, Gall H, Weissmann N, Weidenbach A, et al.: Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors. Respir Res 2005, 6:76.
10. Maurice DH, Palmer D, Tilley DG, Dunkerley HA, Netherton SJ, Raymond DR, et al.: Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol Pharmacol 2003, 64:533-546.
11. Polson JB, Strada SJ: Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu Rev Pharmacol Toxicol 1996, 36:403-427.
12. Torphy TJ: Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998, 157:351-370.
13. Houslay MD, Adams DR: PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 2003, 370:1-18.
14. Wagner RS, Smith CJ, Taylor AM, Rhoades RA: Phosphodiesterase inhibition improves agonist-induced relaxation of hypertensive pulmonary arteries. J Pharmacol Exp Ther 1997, 282:1650-1657.
15. Phillips PG, Long L, Wilkins MR, Morrell NW: cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol 2005, 288:L103-L115.
16. Rabe KF, Tenor H, Dent G, Schudt C, Nakashima M, Magnussen H: Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol 1994, 266:L536-L543.
17. Pauvert O, Salvail D, Rousseau E, Lugnier C, Marthan R, Savineau JP: Characterisation of cyclic nucleotide phosphodiesterase isoforms in the media layer of the main pulmonary artery. Biochem Pharmacol 2002, 63:1763-1772.
18. Schermuly RT, Ghofrani HA, Enke B, Weissmann N, Grimminger F, Seeger W, et al.: Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension. Am J Respir Crit Care Med 1999, 160:1500-1506.
19. Schermuly RT, Roehl A, Weissmann N, Ghofrani HA, Schudt C, Tenor H, et al.: Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange. J Pharmacol Exp Ther 2000, 292:512-520.
20. Palmer D, Tsoi K, Maurice DH: Synergistic inhibition of vascular smooth muscle cell migration by phosphodiesterase 3 and phosphodiesterase 4 inhibitors. Circ Res 1998, 82:852-861.
21. Goncharova EA, Billington CK, Irani C, Vorotnikov AV, Tkachuk VA, Penn RB, et al.: Cyclic AMP-mobilizing agents and glucocorticoids modulate human smooth muscle cell migration. Am J Respir Cell Mol Biol 2003, 29:19-27.
22. Osinski MT, Schror K: Inhibition of platelet-derived growth factor-induced mitogenesis by phosphodiesterase 3 inhibitors: role of protein kinase A in vascular smooth muscle cell mitogenesis. Biochem Pharmacol 2000, 60:381-387.
23. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, et al.: Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43:13S-24S.
24. Mandegar M, Fung YC, Huang W, Remillard CV, Rubin LJ, Yuan JX: Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. Microvasc Res 2004, 68:75-103.
25. Frisdal E, Gest V, Vieillard-Baron A, Levame M, Lepetit H, Eddahibi S, et al.: Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension. Eur Respir J 2001, 18:838-845.
26. Vieillard-Baron A, Frisdal E, Raffestin B, Baker AH, Eddahibi S, Adnot S, et al.: Inhibition of matrix metalloproteinases by lung TIMP-1 gene transfer limits monocrotaline-induced pulmonary vascular remodeling in rats. Hum Gene Ther 2003, 14:861-869.
27. Martinez A, Oh HR, Unsworth EJ, Bregonzio C, Saavedra JM, Stetler-Stevenson WG, et al.: Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator. Biochem J 2004, 383:413-418.
28. Matsui K, Takano Y, Yu ZX, Hi JE, Stetler-Stevenson WG, Travis WD, et al.: Immunohistochemical study of endothelin-1 and matrix metalloproteinases in plexogenic pulmonary arteriopathy. Pathol Res Pract 2002, 198:403-412.
29. Lepetit H, Eddahibi S, Fadel E, Frisdal E, Munaut C, Noel A, et al.: Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension. Eur Respir J 2005, 25:834-842.
30. Peracchia F, Tamburro A, Prontera C, Mariani B, Rotilio D: cAMP involvement in the expression of MMP-2 and MT-MMP1 metalloproteinases in human endothelial cells. Arterioscler Thromb Vasc Biol 1997, 17:3185-3190.
31. McCawley LJ, Li S, Benavidez M, Halbleib J, Wattenberg EV, Hudson LG: Elevation of intracellular cAMP inhibits growth factormediated matrix metalloproteinase-9 induction and keratinocyte migration. Mol Pharmacol 2000, 58:145-151.
32. Shankavaram UT, Lai WC, Netzel-Arnett S, Mangan PR, Ardans JA, Caterina N, et al.: Monocyte membrane type 1-matrix metalloproteinase. Prostaglandin-dependent regulation and role in metalloproteinase-2 activation. J Biol Chem 2001, 276:19027-19032.
33. Zhong ZD, Hammani K, Bae WS, DeClerck YA: NF-Y and Sp1 cooperate for the transcriptional activation and cAMP response of human tissue inhibitor of metalloproteinases-2. J Biol Chem 2000, 275:18602-18610.
34. Wharton J, Strange JW, Moller GM, Growcott EJ, Ren X, Franklyn AP, et al.: Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 2005, 172:105-113.
35. Wang P, Wu P, Ohleth KM, Egan RW, Billah MM: Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol Pharmacol 1999, 56:170-174.
36. Bian H, Zhang J, Wu P, Varty LA, Jia Y, Mayhood T, et al.: Differential type 4 cAMP-specific phosphodiesterase (PDE4) expression and functional sensitivity to PDE4 inhibitors among rats, monkeys and humans. Biochem Pharmacol 2004, 68:2229-2236.
37. Maclean MR, Johnston ED, Mcculloch KM, Pooley L, Houslay MD, Sweeney G: Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension. J Pharmacol Exp Ther 1997, 283:619-624.
38. Liu H, Palmer D, Jimmo SL, Tilley DG, Dunkerley HA, Pang SC, et al.: Expression of phosphodiesterase 4D (PDE4D) is regulated by both the cyclic AMP-dependent protein kinase and mitogen-activated protein kinase signaling pathways. A potential mechanism allowing for the coordinated regulation of PDE4D activity and expression in cells. J Biol Chem 2000, 275:26615-26624.
39. Wong W, Scott JD: AKAP signalling complexes: focal points in space and time. Nat Rev Mol Cell Biol 2004, 5:959-970.
40. Hatzelmann A, Schudt C: Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001, 297:267-279.
41. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R: In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 2001, 297:280-290.
42. Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbroker D, Bethke TD: Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005, 366:563-571.
43. Schermuly RT, Kreisselmeier KP, Ghofrani HA, Samidurai A, Pullamsetti S, Weissmann N, et al.: Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circ Res 2004, 94:1101-1108.
44. Giembycz MA: Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors. Curr Opin Pharmacol 2005, 5:238-244.
45. Hayashi S, Morishita R, Matsushita H, Nakagami H, Taniyama Y, Nakamura T, et al.: Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21. Hypertension 2000, 35:237-243.
46. Li RC, Cindrova-Davies T, Skepper JN, Sellers LA: Prostacyclin induces apoptosis of vascular smooth muscle cells by a cAMP-mediated inhibition of extracellular signal-regulated kinase activity and can counteract the mitogenic activity of endothelin-1 or basic fibroblast growth factor. Circ Res 2004, 94:759-767.
47. Schermuly RT, Yilmaz H, Ghofrani HA, Woyda K, Pullamsetti S, Schulz A, et al.: Inhaled iloprost reverses vascular remodeling in chronic experimental pulmonary hypertension. Am J Respir Crit Care Med 2005, 172:358-363.
48. Jones NA, Boswell-Smith V, Lever R, Page CP: The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro. Pulm Pharmacol Ther 2005, 18:93-101.
49. Kohyama T, Liu X, Zhu YK, Wen FQ, Wang HJ, Fang Q, et al.: Phosphodiesterase 4 inhibitor cilomilast inhibits fibroblast-mediated collagen gel degradation induced by tumor necrosis factor-alpha and neutrophil elastase. Am J Respir Cell Mol Biol 2002, 27:487-494.
50. Oger S, Mehats C, Dallot E, Cabrol D, Leroy MJ: Evidence for a role of phosphodiesterase 4 in lipopolysaccharide-stimulated prostaglandin E2 production and matrix metalloproteinase-9 activity in human amniochorionic membranes. J Immunol 2005, 174:8082-8089.
51. Martin-Chouly CA, Astier A, Jacob C, Pruniaux MP, Bertrand C, Lagente V: Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors. Life Sci 2004, 75:823-840.
52. Cha HJ, Park MT, Chung HY, Kim ND, Sato H, Seiki M, et al.: Ursolic acid-induced down-regulation of MMP-9 gene is mediated through the nuclear translocation of glucocorticoid receptor in HT1080 human fibrosarcoma cells. Oncogene 1998, 16:771-778.
53. Ogawa A, Nakamura K, Matsubara H, Fujio H, Ikeda T, Kobayashi K, et al.: Prednisolone inhibits proliferation of cultured pulmonary arterysmooth muscle cells of patients with idiopathic pulmonary arterial hypertension. Circulation 2005, 112:1806-1812.